ACP
TRVI icon

Acuta Capital Partners’s Trevi Therapeutics TRVI Stock Holding History

Acuta Capital Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-493,735
Closed -$2.7M – 33
2025
Q2 		$2.7M Sell
493,735
-292,226
-37% -$1.82M 3.77% 11
2025
Q1 		$4.94M Buy
785,961
+14,003
+2% +$66.8K 5.73% 6
2024
Q4 		$3.18M Buy
771,958
+481,458
+166% +$1.54M 3.2% 11
2024
Q3 		$970K Buy
290,500
+30,500
+12% +$90.7K 0.79% 26
2024
Q2 		$775K Buy
+260,000
New +$722K 0.65% 24
2022
Q4 		– Sell
-36,302
Closed -$56K – 47
2022
Q3 		$56K Buy
36,302
+1,302
+4% +$4.27K 0.02% 45
2022
Q2 		$98K Buy
+35,000
New +$86K 0.05% 41

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return